This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The role of antiplatelet agents in stroke prevention is well documented, especially for secondary prevention, but many patients with no previous stroke but with other risk factors (high cardiovascular risk, women with diabetes mellitus, chronic kidney disease, peripheral artery disease, or asymptomatic carotid stenosis) can also benefit. The findings of Jung et al.1 are therefore clinically relevant and can be used to reassure patients that even if antiplatelet agents fail to prevent stroke, they can mitigate its severity. Although it is an observational study, a randomized trial to test the effect of antiplatelet agents on ischemic stroke severity might not be ethically acceptable.
Footnotes
Study funding: No targeted funding reported.
Disclosure: Dr. Niewada serves/has served on scientific advisory boards for Boehringer Ingelheim, Amgen, Janssen, Novo-Nordisk, BMS, Lundbeck, UCB, and Pfizer; and has received funding for travel and speaker honoraria from NovoNordisk, Boehringer Ingelheim, GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbott, AstraZeneca, BMS, and Gedeon Richter. He is founder of HealthQuest Company focusing on health technology assessment consulting. Go to Neurology.org for full disclosures.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg